智通财经APP获悉，周五，大麻股集体狂飙，Tilray Brands(TLRY.US)大涨超32%，canopy growth(CGC.US)涨超23%，SNDL(SNDL.US)涨超19%，极光大麻(ACB.US)涨超11%，cronos group(CRON.US)涨超5%。消息面上，多家美国当地媒体报道称，美国总统唐纳德.特朗普预计将推动把 大麻重新归类为"危害性较低的药物"。根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I) ——该类别表示无医疗用途且具有高滥用潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性 潜力较低的物质类别。 ...

The stock prices of major cannabis companies like Tilray Brands (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC) skyrocketed 34.88% and 27.46%, respectively, in premarket trading on Friday, following reports of President Donald Trump‘s plans to relax federal regulations on marijuana. Meanwhile, Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19% and Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) rose 12% and 34.7% respectively. Reclassification Of Cannabis ...

智通财经APP获悉，多家美国当地媒体报道称，美国总统唐纳德·特朗普预计将推动把大麻重新归类 为"危害性较低的药物"，这一最新的市场动态无疑直接推动美国大麻类生产商股票周五在美股盘前交易 中大幅上涨。涨幅居前的包括：Tilray Brands(TLRY.US)盘前大涨超30%，Canopy Growth(CGC.US)涨 23%，Aurora Cannabis(ACB.US)涨20%，SNDL(SNDL.US)涨14%，Cronos Group(CRON.US)涨12%。 根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I)——该类别表示无医疗用途且具有高滥用 潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性潜力较低的物质类别。 据报道，特朗普当地时间周四早些时候与美国众议院议长迈克·约翰逊、特朗普亲自提名的卫生与公众 服务部(HHS)部长小罗伯特·F·肯尼迪、医疗保险和医疗补助服务中心(CMS)署长梅赫梅特·奥兹，以及数 位大麻行业高管通话，讨论该事项。 不过报道称，联系到的一名白宫高级官员表示，特朗普本人尚未给出最终的行政决定。 附表III药物具有已被普遍接受的医疗用途，但仍存 ...

US-listed cannabis stocks saw sharp premarket gains on Friday after fresh reporting pointed to a possible change in federal marijuana policy under President Donald Trump. The development revived inves... ...

Latest Innovation Brings New Proprietary Cultivar to Polish Patients Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Raf, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include Cannabis flos Aurora 27/1, MedReleaf, C ...

Here Is How Reform Will Help Most Marijuana Stocks In The MarketWith 2026 showing to be a big year for reform, how will this impact marijuana stocks? Looking back over the years, it is clear that marijuana stocks have seen their best trading when positive news on reform is released. The speculation of what could happen drives the market action up often. If investors feel the reform is important enough, you’ll then see some increased buying action.What many know already is the long, grueling, intense volatil ...

Core Insights - Aurora Cannabis Inc. has appointed Kerry Miller as Managing Director for Australia and New Zealand, effective January 15, 2026, to drive growth in these markets [1][2] Group 1: Leadership Appointment - Kerry Miller brings 35 years of experience in consumer packaged goods, with a notable 25-year tenure at Reckitt Benckiser and nearly 10 years at Unilever, where he led global initiatives and transformation programs [3] - Miller expressed enthusiasm about joining Aurora at a pivotal moment for the company, focusing on expanding access to medical cannabis and enhancing innovation and partnerships [2] Group 2: Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company offers a diverse portfolio of brands, including adult-use brands like Drift and San Rafael '71, and medical brands such as MedReleaf and CanniMed [4] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [4]

Core Insights - Aurora Cannabis Inc. has announced a distribution partnership with Leafio to enhance access to medical cannabis for patients in Australia [1][2] - The partnership aims to provide educational resources for healthcare professionals and improve patient outcomes through a reliable supply chain [2][5] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across multiple regions including Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of brands, including MedReleaf, CanniMed, and Whistler Medical Marijuana Co., and is focused on high-quality cannabis products [3] Partnership Details - The agreement allows Leafio to distribute Aurora's medical cannabis products through its nationwide supply chain, which services over 4,000 pharmacies in Australia [2][5] - The partnership is expected to enhance research, product innovation, and clinician education, ultimately benefiting the medical cannabis industry in the region [2][6] Market Impact - This collaboration is positioned to significantly improve access to consistent, high-quality medical cannabis for Australian patients [2][6] - The partnership reflects Aurora's commitment to expanding its leadership in the Australian market and enhancing patient access to medical cannabis [2][6]

Industry Overview - The recent passage of a new bill that reverses the 2018 Farm Bill has created uncertainty for marijuana stock investors, as it alters the legal landscape for hemp and cannabis operators in the U.S. [1][2] - This legislative change is viewed as a potential setback for the industry, raising questions about the future of legal cannabis operations and the preservation of cannabis genetics [2]. Impact on Marijuana Stocks - The effect of the new bill on marijuana stock trading and investment remains uncertain, but there is speculation that federal reform could lead to increased government control similar to that of tobacco and alcohol industries [3]. - Despite the challenges posed by the new legislation, there are still notable marijuana stocks that investors are encouraged to monitor for potential growth if federal reform is enacted [3]. Company Highlights - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products, with recent financial results indicating a strong operational presence [4]. - **Cronos Group Inc.**: Focuses on the cultivation and marketing of cannabis products, reporting significant earnings in its Q2 2025 results [7]. - **SNDL Inc.**: Reports a 9% increase in net revenue quarter-over-quarter and a 6% increase year-over-year in Q3 2025, achieving record levels of consolidated net revenue and gross profit [11][14]. Financial Performance - Aurora Cannabis reported a 15% year-over-year increase in global medical cannabis net revenue, reaching $70.5 million, with a 52% growth in Adjusted EBITDA to $15.4 million [9]. - SNDL's Q3 2025 financial results showed net revenue of $244.2 million, reflecting a growth rate of 3.1%, and a gross profit of $64.2 million, representing a 1.9% increase year-over-year [15].

Core Insights - Aurora Cannabis Inc. (NASDAQ: ACB) demonstrated strong top-line growth and profitability, with positive cash flow anticipated soon [1][3] Financial Performance - The top line increased by 11%, primarily driven by robust medical cannabis demand from Germany, Poland, and Australia [2] - Gross margin expanded significantly to 61%, led by the medical business, outperforming the broader cannabis industry [2] Future Outlook - Management expects a return to positive free cash flow in the fiscal third quarter ending in December [3] - Aurora maintains a strong balance sheet with C$142 million in cash and no cannabis-related debt [3] Competitive Positioning - The re-certification of Aurora's EU-GMP and the expansion of the Leuna facility enhance visibility for sustainable growth and margin improvement [3] - ACB is trading at 0.9x forward sales and 6.5x EV/EBITDA, below peer averages, indicating attractive valuation despite strong industry positioning [4]